BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

  BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1
  as a Breast Cancer-Specific Marker

   - FSIP1 is one component of a panel of markers comprising PanC-Dx^TM, a
                         blood-based cancer screen -

Business Wire

ALAMEDA, Calif. -- August 5, 2013

BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation
today announced the publication of a scientific report on the gene FSIP1 and
its potential as a marker for breast cancer. The paper, published in the
peer-reviewed journal Biomarkers in Medicine and available online today,
describes the microarray-based approach used to identify FSIP1 as a breast
cancer biomarker with significantly elevated expression in breast tumors
expressing the estrogen receptor, which represents 70-80% of all breast
cancers. In addition to elevated gene expression, FSIP1 protein was also
expressed within tumors at significant levels whereas little to no expression
was found in most normal tissues, including healthy breast tissue. Combined,
these findings lay the foundation for novel diagnostic and therapeutic
strategies, including the measurement of FSIP1 in the blood as a screen for
the presence of cancer, as well as targeting of FSIP1 as an antigen in cancer
immunotherapy approaches.

Based on large unmet need, market size, and data generated thus far from
patient sample screening, OncoCyte is initially focusing its efforts on
identifying biomarkers that may be used to detect and monitor breast and
bladder cancers. OncoCyte has been developing, characterizing, and
manufacturing monoclonal antibodies for use in detecting breast cancer, in
preparation for the initiation of the first clinical study of PanC-Dx^TM and
is currently working with a select group of cancer researchers to finalize a
study protocol for submission to the institutional review boards of the study
sites. If clinical trials are successful, OncoCyte intends to launch
PanC-Dx^TM as an in vitro diagnostic (IVD) in Europe before seeking FDA
approval required to market PanC-Dx^TM in the United States.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem®-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix
for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

About OncoCyte Corporation

OncoCyte Corporation is a majority-owned subsidiary of BioTime, Inc.
OncoCyte's mission is to develop novel products for the diagnosis and
treatment of cancer in order to improve both the quality and length of life of
cancer patients. OncoCyte's molecular diagnostics division is developing
products for earlier detection of a variety of cancers. In addition to its
diagnostic product line, OncoCyte is developing cellular therapies to treat
cancer based on the unique biology of vascular precursor cells. The goal of
OncoCyte's therapeutic research efforts is to derive vascular cells that can
be engineered to deliver a toxic payload to the developing blood vessels of a
malignant tumor to destroy the tumor without killing nearby normal tissues in
the body. Additional information on OncoCyte can be found on the web at
www.oncocyte.com

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com

Contact:

BioTime, Inc.
Robert Peabody
Sr. VP & CFO
510-521-3390, ext 302
rpeabody@biotimemail.com
or
Judith Segall
510-521-3390, ext 301
jsegall@biotimemail.com
 
Press spacebar to pause and continue. Press esc to stop.